Blue Biofuels (BIOF) 10-K 26 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Feb. 29, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-54942
Entity Registrant Name	BLUE BIOFUELS, INC.
Entity Central Index Key	0001549145
Entity Tax Identification Number	45-4944960
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3710 Buckeye Street
Entity Address, Address Line Two	Suite 120
Entity Address, City or Town	Palm Beach Gardens
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33410
City Area Code	(888)
Local Phone Number	607-3555
Trading Symbol	BIOF
Title of 12(g) Security	Common Stock par value $0.001
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float				$ 29,189,366
Entity Common Stock, Shares Outstanding			303,115,963
Documents Incorporated by Reference [Text Block]	None
Document Financial Statement Error Correction [Flag]	false
Auditor Name	BF Borgers CPA PC	Prager Metis CPAs, LLC
Auditor Firm ID	5041	273
Auditor Location	Lakewood, CO	Hackensack, New Jersey

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 41,008	$ 211,901
Prepaid expenses	35,750	43,119
TOTAL CURRENT ASSETS	76,758	255,020
Other assets
Property and equipment, net of accumulated depreciation and amortization of $243,089 and $127,178 at December 31, 2023 and December 31,2022, respectively	587,308	420,115
Security deposits	30,276	30,276
Right of Use Assets, net of accumulated amortization	81,091	178,399
Patents	254,786	222,109
TOTAL OTHER ASSETS	953,461	850,899
TOTAL ASSETS	1,030,219	1,105,919
Current liabilities
Right of Use Lease Liability - Current	85,983	95,172
Chapter 11 Settlement		50,000
Interest Payable - Related Party	143,406	76,138
TOTAL CURRENT LIABILITIES	1,503,169	638,721
Long term liabilities
Right of Use Lease Liability, net of current portion		85,983
Notes Payable — Other	266,570	216,570
TOTAL LONG TERM LIABILITIES	3,088,132	2,824,115
TOTAL LIABILITIES	4,591,301	3,462,836
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 302,750,963 issued and outstanding at December 31, 2023, and 289,941,623 issued and outstanding at December 31, 2022.	302,751	289,942
Additional paid-in capital	51,972,947	50,134,727
Accumulated deficit	(55,836,780)	(52,781,586)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(3,561,082)	(2,356,917)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,030,219	1,105,919
Nonrelated Party [Member]
Current liabilities
Accounts payable	22,798	37,135
Related Party [Member]
Current liabilities
Accounts payable	72,670	72,670
Deferred wages and director’s fees - Related party	828,312	307,606
Convertible Notes Payable — Related Party	350,000
Long term liabilities
Notes Payable — Related Party	$ 2,821,562	$ 2,521,562

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation and amortization	$ 243,089	$ 127,178
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	302,750,963	289,941,623
Common stock, shares outstanding	302,750,963	289,941,623

Consolidated Statement of Opera

Consolidated Statement of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Revenue
Operating expense:
General and administrative	1,339,789	1,541,959
Research & Development	1,849,967	2,350,218
Loss on disposal of assets	1,159	40,099
Total operating expenses	3,190,915	3,932,276
Loss from operations:	(3,190,915)	(3,932,276)
Other (income) expense:
Government Grants	(233,500)
Common Stock Recission		(1,500)
Interest expense - other	8,416	2,560
Total other (income) expense	(135,721)	27,907
Income (Loss) before provisions for income taxes	(3,055,194)	(3,960,183)
Provisions for income taxes
Net Income / (Loss):	$ (3,055,194)	$ (3,960,183)
Net income (loss) per share	$ (0.010)	$ (0.014)
Weighted average common shares outstanding
Basic	299,950,813	278,830,924
Related Party [Member]
Other (income) expense:
Interest expense - related party	$ 89,363	$ 26,847

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 274,004		$ 47,151,353	$ (48,821,403)	$ (1,396,046)
Balance, shares at Dec. 31, 2021	274,003,883
Issuance of common stock for services	$ 812		135,738		$ 136,550
Issuance of common stock for services, shares	812,119				812,119
Issuance of warrants for services			9,773		$ 9,773
Warrants exercised	$ 7,000		98,000		105,000
Warrants exercised, shares	7,000,000
Issuance of common stock and warrants for cash through PPM	$ 7,787		1,160,213		1,168,000
Issuance of common stock and warrants for cash through PPM, shares	7,786,664
Issuance of common stock in exchange for debt
Vesting of options under the employee, director plan			1,565,589		1,565,589
Net Income (Loss)				(3,960,183)	(3,960,183)
Employee stock options exercised	$ 350		15,550		$ 15,900
Employee stock options exercised, shares	350,000				350,000
Stock Recinded	$ (11)		(1,489)		$ (1,500)
Stock Recinded, shares					(11,043)
Balance at Dec. 31, 2022	$ 289,942		50,134,727	(52,781,586)	$ (2,356,917)
Balance, shares at Dec. 31, 2022	289,941,623
Issuance of common stock for services	$ 174		29,126		$ 29,300
Issuance of common stock for services, shares	174,194				174,194
Issuance of warrants for services			84,677		$ 84,677
Warrants exercised	$ 5,950		91,301		97,251
Warrants exercised, shares	5,950,148
Issuance of common stock and warrants for cash through PPM	$ 6,685		996,087		1,002,772
Issuance of common stock and warrants for cash through PPM, shares	6,684,998
Issuance of common stock in exchange for debt
Vesting of options under the employee, director plan			637,028		637,028
Net Income (Loss)				(3,055,194)	$ (3,055,194)
Employee stock options exercised, shares					0
Balance at Dec. 31, 2023	$ 302,751		$ 51,972,946	$ (55,836,780)	$ (3,561,082)
Balance, shares at Dec. 31, 2023	302,750,963

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Warrants issued for services	794,000	77,333
Vesting of options previously issued under employee director plan	4,385,000	12,560,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net Income (Loss)	$ (3,055,194)	$ (3,960,183)
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization	216,785	138,464
Stock based compensation for services	29,300	136,550
Recission of stock		(1,500)
Net Issuance of options and warrants for services	721,705	1,575,362
Loss on Disposal of assets	1,159	40,099
Changes in operating assets and liabilities
Prepaid expenses	7,368	1,933
Accrued interest - related party	67,269	26,846
Accounts payable and accrued liabilities	506,369	92,887
Right of use lease	(95,172)	(86,601)
Net cash used in operating activities	(1,600,411)	(2,036,143)
Cash flows from investing activities
Net purchase of property and equipment	(287,828)	(138,170)
Patent Costs	(32,677)	(67,350)
Net cash from (used in) investing activities	(320,505)	(205,520)
Cash flows from financing activities
Net proceeds from issuance of common stock	1,002,772	1,168,000
Net proceeds from issuance of convertible notes	700,000
Proceeds from exercise of warrants and options	97,251	120,900
Payment of debt	(50,000)
Net cash provided by financing activities	1,750,023	1,288,900
Net increase (decrease) in cash and cash equivalents	(170,893)	(952,763)
Cash and cash equivalent at beginning of the period	211,901	1,164,664
Cash and cash equivalent at end of the period	41,008	211,901
Cash paid during the period for
Interest
Taxes
Supplemental schedule of non-cash activities
Issuance of warrants for services	84,677	9,773
Issuance of common stock for services	29,300	136,550
Cashless conversion of warrants/options
Conversion of convertible debenture to common stock

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	NOTE 1 – ORGANIZATION Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels, and lignin technologies sectors. In early 2018, our chief executive officer (“CEO”) Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and the Company filed, and received, two patents for this technology (U.S. Patent No. 10,994,255 and 11,484,858B2), and has subsequently been granted the firrst in Japan and El Salvador. The Company also filed for both patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. Further, the company has filed for 6 other patents in the United States which are currently pending. The CTS process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin. The CTS system converts plant-based feedstock into one primary product, soluble sugars, which can be further processed into cellulosic ethanol and other biofuels like jet fuel, and potentially into bio chemicals. In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour. In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. The Company believes that it can optimize the pre and post processing elements at this pilot scale plant to finalize design and operational parameters to provide operating cost estimates of a full-scale commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems. In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline. The license agreement with Vertimass is the subject to a confidentiality agreement between the parties. Plan of Operation The total process from cellulosic feedstock to SAF consists basically of three steps: 1) Conversion from feedstock to fermentable cellulosic sugars (CTS) 2) Ferment the cellulosic sugars into cellulosic ethanol. 3) Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed. In January 2024, the Company formed a 50-50 joint venture partnership with Vertimass called VertiBlue Fuels, LLC, that has the mission to build an ethanol-to-SAF facility in Florida with the initial goal to produce around 10 million gallons of Sustainable Aviation Fuel (SAF) and related products, and then expand SAF and related product production to approximately 70 million gallon per year

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of December 31, 2023, the Company has incurred accumulated losses of $ 55,836,780 Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates. Cash and Cash Equivalents All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents. Stock Compensation The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation”. Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance. Stock-based Compensation Valuation Methodology Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate. The stock compensation issued for services during the years ended December 31, 2023, and December 31, 2022, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the years ended December 31, 2023, and December 31, 2022: SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION 1/5/22 4/19/22 6/21/22 9/30/22 12/30/22 Risk-free interest rate 1.71 % 2.93 % 3.38 % 4.06 % 3.99 % Expected life 10 10 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % Expected volatility 133.99 % 133.42 % 134.52 % 128.59 % 124.11 % BIOF common stock fair value $ 0.259 $ 0.165 $ 0.167 $ 0.167 $ 0.145 2/10/23 2/14/23 3/1/23 3/31/23 4/5/23 4/11/23 Risk-free interest rate 3.93 % 3.77 % 4.01 % 3.60 % 3.30 % 3.54 % Expected life 5 10 10 5 10 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 123.25 % 123.26 % 123.52 % 120.71 % 119.51 % 119.39 % BIOF common stock fair value $ 0.159 $ 0.159 $ 0.177 $ 0.166 $ 0.154 $ 0.145 4/26/23 6/5/23 7/13/23 7/26/23 10/16/23 11/1/23 12/27/23 Risk-free interest rate 3.46 % 3.77 % 3.93 % 3.86 % 4.72 % 4.67 % 3.78 % Expected life 5 7 5 5 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 119.28 % 103.20 % 90.70 % 87.22 % 81.19 % 81.11 % 91.10 % BIOF common stock fair value $ 0.165 $ 0.170 $ 0.160 $ 0.160 $ 0.131 $ 0.123 $ 0.106 Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 10 Patent Capitalization If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end products are expected to be sugar, ethanol, and SAF, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process. Research and Development The Company expenses all research and development costs as incurred. For the years ended December 31, 2023, and December 31, 2022, the amounts charged to research and development expenses were $ 1,849,967 2,350,218 Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. Under ASC 606, revenue is recognized when the following criteria are met: 1. persuasive evidence of an arrangement exists; 2. product has been delivered or the services have been rendered to the customer; 3. the sales price is fixed or determinable; and, 4. collectability of the fee or sales price is reasonably assured. The Company currently has no customers. The Company’s revenues are expected to be derived principally from products sold through joint ventures and corporate owned plants. However, no sales have occurred through those revenue streams to date. The company will recognize revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms. Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. As of December 31, 2023, the Company has convertible instruments but none that have intrinsic value to conversion options, hence no bifurcation is necessary. Accounting for Derivative Instruments The Company issues debentures where the number of shares into which a debenture can be converted is not fixed. (For example, when a debenture converts at a discount to market based on the stock price on the date of conversion.) The Company analyzes the embedded conversion option of the convertible debentures to determine if it should be bifurcated from the host contract and recorded at their fair value. In accounting for derivatives, the Company records a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the beneficial conversion feature. The discount is then amortized over the life of the debenture and the derivative liability is adjusted periodically according to stock price fluctuations. At the time of conversion, any remaining derivative liability is charged to additional paid-in capital. For purposes of determining derivative liability, the Company uses Black-Scholes modeling for computing historic volatility. As of December 31, 2023, the Company has no derivative instruments. Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. Investments in non-consolidated affiliates Investments in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. The Company monitors its investment for impairment at least annually and makes appropriate reductions in the carrying value if it determines that an impairment charge is required based on qualitative and quantitative information. As of December 31, 2023, the Company had no investments in non-consolidated affiliates. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented. Profit (Loss) per Common Share Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) At December 31, 2022, the Company did not identify any assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT SCHEDULE OF PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT Life December 31, 2023 December 31, 2022 Building and Improvements 15 $ 9,370 $ 9,370 Machinery and Equipment 10 $ 795,606 $ 512,450 Furniture and Fixtures 5 $ 13,596 $ 13,649 Computer Equipment 3 $ 11,825 $ 11,824 Property and Equipment, gross $ 830,397 $ 547,293 Less Accumulated Depreciation $ (243,089 ) $ (127,178 ) Property and Equipment $ 587,308 $ 420,115 Total depreciation expense was $ 119,476 55,601 In the fiscal year ended December 31, 2023, the Company disposed of laboratory equipment and machinery that was no longer in use for a total of $ 3500 8171 3,513 1,158 1,185 240,898 199,614 40,099

PATENTS

PATENTS	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS	NOTE 5 – PATENTS The Company has obtained two patents and has applied for three more patents on its technology, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $ 254,786

DEBT

DEBT	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 6 – DEBT Details of each remaining debt, including those that have been paid off or renegotiated during 2023, are indicated below. Notes Payable – Related Parties On December 13, 2023, and also on August 10, 2023, and on June 30, 2023, the Company entered into a long-term convertible notes with board member Chris Kneppers, with principal balances of $ 10,000 50,000 50,000 10 The Notes are convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5 733,333 On November 11, 2023, and also on July 7, 2023, the Company entered into two long-term convertible notes with board member Edmund Burke, with a total principal balance of $ 15,000 25,000 accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 and 30,000 respectively every 12 months instead of interest, with a minimum of 80,000 warrants. 0.13 307,692 In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $ 100,000 0.13 769,231 In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $ 150,000 accrued warrants, with a strike price of 15 cents and an expiration of 5 0.13 1,153,846 In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $ 250,000 0.13 1,923,077 In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent ( 6 The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. 240,990 579,942 1.5 1.25 On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $ 100,000 May 1, 2018 2,000,000 84,000 5,000,000 100,000 On May 15, 2018, the Company entered into a short term loan with Christopher Jemapete, with a principal balance of $ 50,000 May 16, 2019 5 1,250,000 1,000,000 0.10 5 36,250 24,449 315 50,315 On May 15, 2018, the Company entered into a short term loan with Pamela Jemapete, with a principal balance of $ 50,000 May 16, 2019 5 1,250,000 1,000,000 0.10 5 36,250 24,449 315 50,315 Notes Payable – Chapter 11 Settlement On July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $ 2,694,577 th 13,650 50,000 1.5 0.30 ten 50,000 Notes Payable – Other In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49 96,570 6 The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $ 96,570 In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $ 143,000 May 30, 2018 8 43,000 35 500,000 39,500 120 40,000 100,000 5 In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $ 165,000 September 21, 2018 8 15,000 40 500,000 14,500 120 100,000 5 On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $ 32,000 20,000 A summary of all Notes that remain of those indicated in the Notes above is as follows: SCHEDULE OF NOTES PAYABLE Notes Payable December 31, 2023 December 31, 2022 Short Term Chapter 11 Settlement $ 0 $ 50,000 Short Term Convertible Notes – Related Party $ 350,000 $ 0 Long Term Convertible Notes Payable – Related Party $ 300,000 $ 0 Long Term Notes Payable from future revenue — Related Party $ 1,700,630 $ 1,700,630 Long Term Notes Payable from future revenue — Other $ 120,000 $ 120,000 Long Term Note Payable from future profits — Related Party $ 820,932 $ 820,932 Long Term Note Payable from future profits — Other $ 96,570 $ 96,570 TOTAL NOTES $ 3,388,132 $ 2,788,132 Only $ 100,000 3,388,132 300,000 300,000 2,738,132 2,417,502 2,738,132

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7 – STOCKHOLDERS’ EQUITY The total number of shares of capital stock, which the Company has authority to issue, is 1,010 1000 0.001 10 0.001 302,750,963 no Holders of shares of Common stock shall be entitled to cast one vote for each share held In the year ended December 31, 2023, the company issued an aggregate of 174,194 29,300 In the year ended December 31, 2023, the Company issued an aggregate of 794,000 84,677 In the year ended December 31, 2023, 5,950,148 97,251 In the year ended December 31, 2023, no In the year ended December 31, 2023, the Company issued 6,684,998 1,002,772 In the year ended December 31, 2023, the Company issued unvested options under its Employee & Directors Stock Option Plan to purchase an aggregate of 17,150,000 ten years 0.19 0.20 2,835,613 1,000,000 157,939 3,385,000 479,089 In the year ended December 31, 2022, the company issued an aggregate of 812,119 136,550 In the year ended December 31, 2022, the Company issued an aggregate of 77,333 9,773 2,000,000 In the year ended December 31, 2022, 7,000,000 105,000 In the year ended December 31, 2022, 350,000 15,900 In the year ended December 31, 2022, 11,043 In the year ended December 31, 2022, the Company issued 7,786,664 1,168,000 In the year ended December 31, 2022, the Company issued options under its Employee & Directors Stock Option Plan to purchase an aggregate of 2,000,000 ten years 0.17 319,327 100,000 12,560,000 1,565,589 Share-Based Awards Stock option activity under the 2021 ESOP for the year ending December 31, 2023, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2022 51,080,000 $ 0.13 7.87 $ 6,791,500 Awarded 18,150,000 $ 0.19 8.99 $ - Exercised 500,000 $ 0.05 - $ 15,875 Expired or Rescinded 7,175,000 $ 0.19 - $ - Outstanding as of December 31, 2023 61,555,000 $ 0.15 7.20 $ 45,763 Vested as of December 31, 2023 28,180,000 $ 0.13 6.33 $ 42,500 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2021 50,034,466 $ 0.13 8.53 $ 6,495,981 Awarded 4,000,000 $ 0.18 7.14 $ 700,000 Exercised 350,000 $ 0.05 - $ 15,900 Expired or Rescinded 2,604,466 $ 0.15 - $ 388,581 Outstanding as of December 31, 2022 51,080,000 $ 0.13 7.87 $ 6,791,500 Vested as of December 31, 2022 24,420,000 $ 0.12 6.98 $ 2,982,250 Warrant activity for the year ending December 31, 2023, is as follows: SCHEDULE OF WARRANT ACTIVITY Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406 Awarded 7,478,998 $ 0.24 4.35 $ - Exercised 5,450,148 $ 0.01 - $ 373,299 Expired 2,401,332 $ 0.15 - $ - Outstanding as of December 31, 2023 24,015,976 $ 0.22 3.31 $ 91,690 Vested as of December 31, 2023 24,015,976 $ 0.22 3.31 $ 91,690 Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2021 28,571,961 $ 0.12 2.17 $ 3,352,149 Awarded 7,863,997 $ 0.25 4.75 $ 1,962,133 Exercised 7,000,000 $ 0.02 - $ 105,000 Expired 5,047,500 $ 0.27 - $ 1,367,875 Outstanding as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406 Vested as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES The reconciliation of income tax benefit at the U.S. statutory rate of 21 SCHEDULE OF RECONCILIATION BETWEEN STATUTORY TAX RATE AND EFFECTIVE TAX RATE 31-Dec-23 31-Dec-22 Statutory federal income tax rate -21 % -21 % State income tax, net of federal benefits -5.5 % -5.5 % Valuation Allowance 26.5 % 26.5 % Income tax provision (benefit) 0 % 0 % The provisional (benefit) for income tax is summarized as follows: SCHEDULE OF INCOME TAX PROVISION 31-Dec-23 31-Dec-22 Federal Current $ - $ - Deferred (642,785 ) (831,638 ) State Current - - Deferred (168,349 ) (217,810 ) Change in valuation allowance 811,134 1,049,448 Income tax provision (benefit) $ - $ - The tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of December 31, 2023 and 2022 are as follows: SCHEDULE OF TAX EFFECTS OF PRINCIPAL TEMPORARY DIFFERENCES THAT GIVE RISE TO DEFERRED TAX ASSETS 31-Dec-23 31-Dec-22 Years Ended 31-Dec-23 31-Dec-22 Deferred tax asset Net operating loss carryovers (federal) $ 13,561,765 $ 12,752,139 Total deferred tax assets 13,561,765 12,752,139 Valuation Allowance (13,561,765 ) (12,752,139 ) Deferred tax asset, net of allowance $ - $ - As of December 31, 2023, and 2022, the Company had approximately $ 51,176,471 48,121,278 2033 Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35 21 The Company files U.S. Federal and Florida tax returns that are subject to audit by tax authorities. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 - COMMITMENTS AND CONTINGENCIES Litigation The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time. Leases The Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. 84,100 3 102,950 3 3,600 ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for 18.2 6,370 5 167.6 24,721 5 Total rent expense for the years ending December 31, 2023, and 2022, were $ 214,902 139,083 The following table provides the components of the lease expense for the periods indicated: SCHEDULE OF COMPONENTS OF THE LEASE EXPENSE December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Finance Lease Cost: Amortization of ROU assets $ - $ - Interest on lease liabilities 0 0 Operating lease cost 95,172 86,601 Short-term lease cost 0 0 Total lease expense 95,172 86,601 The following table provides supplemental cash flow and other information related to leases for the periods indicated: SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases ( 1 $ - $ - Operating cash flows from finance leases 0 0 Financing cash flows from finance leases 0 0 ROU assets obtained in exchange for new lease liabilities: Finance leases 0 0 Operating leases 0 0 (1) Amounts are included in Other operating activities on the consolidated cash flow statements. The following table provides the lease terms and discount rates for the periods indicated: SCHEDULE OF LEASE TERMS AND DISCOUNT RATES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Weighted-average remaining lease term (years): Finance leases 0 0 Operating leases 0.83 1.83 Weighted-average discount rate: Finance leases N/A N/A Operating leases N/A N/A The following table provides supplemental balance sheet information related to leases at the dates indicated: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Assets Finance lease ROU assets (1) $ - $ - Operating lease ROU assets 81,091 178,399 Liabilities Current Finance lease liabilities 0 0 Operating lease liabilities 85,983 95,172 Noncurrent Finance lease liabilities 0 0 Operating lease liabilities 0 85,983 (1) Amounts are included in Property and equipment, net on the consolidated balance sheets. The following table provides maturities of undiscounted lease liabilities at December 31, 2023 SCHEDULE OF MATURITIES OF UNDISCOUNTED LEASE LIABILITIES Finance Lease Operating Lease 2024 $ - $ 88,365 2025 0 0 Thereafter 0 0 Total lease payments $ - $ 88,365 Less: Interest 0 (2,382 ) Present value of lease liabilities 0 85,983 Less: Current portion of lease obligation 0 (85,983 ) Total long-term lease obligation $ - $ 0 The following table provides maturities of undiscounted lease liabilities at December 31, 2022: Finance Lease Operating Lease 2023 $ - $ 103,465 2024 0 88,365 Thereafter 0 0 Total lease payments - 191,830 Less: Interest - (10,675 ) Present value of lease liabilities - 181,155 Less: Current portion of lease obligation - (95,172 ) Total long-term lease obligation - 85,983

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS Related Transactions The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. 1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6. 2) A board resolution was passed on February 13, 2020, that pledged the pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continue to be owed back pay. The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. However, they may not engage in competing business interests. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were available to be issued. Based on this evaluation, the Company has identified the following subsequent events: Subsequent to December 31, 2023, the Company issued 52,500 4,200 62,500 3,592 Subsequent to December 31, 2023, 133,333 Subsequent to December 31, 2023, 1,775,000 234,350 Subsequent to December 31, 2023, the company issued convertible notes for $ 230,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”).
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.
Stock Compensation	Stock Compensation The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation”. Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.
Stock-based Compensation Valuation Methodology	Stock-based Compensation Valuation Methodology Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate. The stock compensation issued for services during the years ended December 31, 2023, and December 31, 2022, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the years ended December 31, 2023, and December 31, 2022: SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION 1/5/22 4/19/22 6/21/22 9/30/22 12/30/22 Risk-free interest rate 1.71 % 2.93 % 3.38 % 4.06 % 3.99 % Expected life 10 10 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % Expected volatility 133.99 % 133.42 % 134.52 % 128.59 % 124.11 % BIOF common stock fair value $ 0.259 $ 0.165 $ 0.167 $ 0.167 $ 0.145 2/10/23 2/14/23 3/1/23 3/31/23 4/5/23 4/11/23 Risk-free interest rate 3.93 % 3.77 % 4.01 % 3.60 % 3.30 % 3.54 % Expected life 5 10 10 5 10 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 123.25 % 123.26 % 123.52 % 120.71 % 119.51 % 119.39 % BIOF common stock fair value $ 0.159 $ 0.159 $ 0.177 $ 0.166 $ 0.154 $ 0.145 4/26/23 6/5/23 7/13/23 7/26/23 10/16/23 11/1/23 12/27/23 Risk-free interest rate 3.46 % 3.77 % 3.93 % 3.86 % 4.72 % 4.67 % 3.78 % Expected life 5 7 5 5 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 119.28 % 103.20 % 90.70 % 87.22 % 81.19 % 81.11 % 91.10 % BIOF common stock fair value $ 0.165 $ 0.170 $ 0.160 $ 0.160 $ 0.131 $ 0.123 $ 0.106
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 10
Patent Capitalization	Patent Capitalization If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end products are expected to be sugar, ethanol, and SAF, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process.
Research and Development	Research and Development The Company expenses all research and development costs as incurred. For the years ended December 31, 2023, and December 31, 2022, the amounts charged to research and development expenses were $ 1,849,967 2,350,218
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. Under ASC 606, revenue is recognized when the following criteria are met: 1. persuasive evidence of an arrangement exists; 2. product has been delivered or the services have been rendered to the customer; 3. the sales price is fixed or determinable; and, 4. collectability of the fee or sales price is reasonably assured. The Company currently has no customers. The Company’s revenues are expected to be derived principally from products sold through joint ventures and corporate owned plants. However, no sales have occurred through those revenue streams to date. The company will recognize revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. As of December 31, 2023, the Company has convertible instruments but none that have intrinsic value to conversion options, hence no bifurcation is necessary.
Accounting for Derivative Instruments	Accounting for Derivative Instruments The Company issues debentures where the number of shares into which a debenture can be converted is not fixed. (For example, when a debenture converts at a discount to market based on the stock price on the date of conversion.) The Company analyzes the embedded conversion option of the convertible debentures to determine if it should be bifurcated from the host contract and recorded at their fair value. In accounting for derivatives, the Company records a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the beneficial conversion feature. The discount is then amortized over the life of the debenture and the derivative liability is adjusted periodically according to stock price fluctuations. At the time of conversion, any remaining derivative liability is charged to additional paid-in capital. For purposes of determining derivative liability, the Company uses Black-Scholes modeling for computing historic volatility. As of December 31, 2023, the Company has no derivative instruments.
Common Stock Purchase Warrants and Other Derivative Financial Instruments	Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
Investments in non-consolidated affiliates	Investments in non-consolidated affiliates Investments in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. The Company monitors its investment for impairment at least annually and makes appropriate reductions in the carrying value if it determines that an impairment charge is required based on qualitative and quantitative information. As of December 31, 2023, the Company had no investments in non-consolidated affiliates.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.
Profit (Loss) per Common Share	Profit (Loss) per Common Share Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.
Fair Value Measurements	Fair Value Measurements The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) At December 31, 2022, the Company did not identify any assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION	The stock compensation issued for services during the years ended December 31, 2023, and December 31, 2022, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the years ended December 31, 2023, and December 31, 2022: SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION 1/5/22 4/19/22 6/21/22 9/30/22 12/30/22 Risk-free interest rate 1.71 % 2.93 % 3.38 % 4.06 % 3.99 % Expected life 10 10 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % Expected volatility 133.99 % 133.42 % 134.52 % 128.59 % 124.11 % BIOF common stock fair value $ 0.259 $ 0.165 $ 0.167 $ 0.167 $ 0.145 2/10/23 2/14/23 3/1/23 3/31/23 4/5/23 4/11/23 Risk-free interest rate 3.93 % 3.77 % 4.01 % 3.60 % 3.30 % 3.54 % Expected life 5 10 10 5 10 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 123.25 % 123.26 % 123.52 % 120.71 % 119.51 % 119.39 % BIOF common stock fair value $ 0.159 $ 0.159 $ 0.177 $ 0.166 $ 0.154 $ 0.145 4/26/23 6/5/23 7/13/23 7/26/23 10/16/23 11/1/23 12/27/23 Risk-free interest rate 3.46 % 3.77 % 3.93 % 3.86 % 4.72 % 4.67 % 3.78 % Expected life 5 7 5 5 5 5 5 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Expected volatility 119.28 % 103.20 % 90.70 % 87.22 % 81.19 % 81.11 % 91.10 % BIOF common stock fair value $ 0.165 $ 0.170 $ 0.160 $ 0.160 $ 0.131 $ 0.123 $ 0.106

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT Life December 31, 2023 December 31, 2022 Building and Improvements 15 $ 9,370 $ 9,370 Machinery and Equipment 10 $ 795,606 $ 512,450 Furniture and Fixtures 5 $ 13,596 $ 13,649 Computer Equipment 3 $ 11,825 $ 11,824 Property and Equipment, gross $ 830,397 $ 547,293 Less Accumulated Depreciation $ (243,089 ) $ (127,178 ) Property and Equipment $ 587,308 $ 420,115

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE	A summary of all Notes that remain of those indicated in the Notes above is as follows: SCHEDULE OF NOTES PAYABLE Notes Payable December 31, 2023 December 31, 2022 Short Term Chapter 11 Settlement $ 0 $ 50,000 Short Term Convertible Notes – Related Party $ 350,000 $ 0 Long Term Convertible Notes Payable – Related Party $ 300,000 $ 0 Long Term Notes Payable from future revenue — Related Party $ 1,700,630 $ 1,700,630 Long Term Notes Payable from future revenue — Other $ 120,000 $ 120,000 Long Term Note Payable from future profits — Related Party $ 820,932 $ 820,932 Long Term Note Payable from future profits — Other $ 96,570 $ 96,570 TOTAL NOTES $ 3,388,132 $ 2,788,132

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	Stock option activity under the 2021 ESOP for the year ending December 31, 2023, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2022 51,080,000 $ 0.13 7.87 $ 6,791,500 Awarded 18,150,000 $ 0.19 8.99 $ - Exercised 500,000 $ 0.05 - $ 15,875 Expired or Rescinded 7,175,000 $ 0.19 - $ - Outstanding as of December 31, 2023 61,555,000 $ 0.15 7.20 $ 45,763 Vested as of December 31, 2023 28,180,000 $ 0.13 6.33 $ 42,500 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2021 50,034,466 $ 0.13 8.53 $ 6,495,981 Awarded 4,000,000 $ 0.18 7.14 $ 700,000 Exercised 350,000 $ 0.05 - $ 15,900 Expired or Rescinded 2,604,466 $ 0.15 - $ 388,581 Outstanding as of December 31, 2022 51,080,000 $ 0.13 7.87 $ 6,791,500 Vested as of December 31, 2022 24,420,000 $ 0.12 6.98 $ 2,982,250
SCHEDULE OF WARRANT ACTIVITY	Warrant activity for the year ending December 31, 2023, is as follows: SCHEDULE OF WARRANT ACTIVITY Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406 Awarded 7,478,998 $ 0.24 4.35 $ - Exercised 5,450,148 $ 0.01 - $ 373,299 Expired 2,401,332 $ 0.15 - $ - Outstanding as of December 31, 2023 24,015,976 $ 0.22 3.31 $ 91,690 Vested as of December 31, 2023 24,015,976 $ 0.22 3.31 $ 91,690 Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ($0’s) Outstanding as of December 31, 2021 28,571,961 $ 0.12 2.17 $ 3,352,149 Awarded 7,863,997 $ 0.25 4.75 $ 1,962,133 Exercised 7,000,000 $ 0.02 - $ 105,000 Expired 5,047,500 $ 0.27 - $ 1,367,875 Outstanding as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406 Vested as of December 31, 2022 24,388,458 $ 0.16 2.83 $ 3,841,406

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF RECONCILIATION BETWEEN STATUTORY TAX RATE AND EFFECTIVE TAX RATE	SCHEDULE OF RECONCILIATION BETWEEN STATUTORY TAX RATE AND EFFECTIVE TAX RATE 31-Dec-23 31-Dec-22 Statutory federal income tax rate -21 % -21 % State income tax, net of federal benefits -5.5 % -5.5 % Valuation Allowance 26.5 % 26.5 % Income tax provision (benefit) 0 % 0 %
SCHEDULE OF INCOME TAX PROVISION	The provisional (benefit) for income tax is summarized as follows: SCHEDULE OF INCOME TAX PROVISION 31-Dec-23 31-Dec-22 Federal Current $ - $ - Deferred (642,785 ) (831,638 ) State Current - - Deferred (168,349 ) (217,810 ) Change in valuation allowance 811,134 1,049,448 Income tax provision (benefit) $ - $ -
SCHEDULE OF TAX EFFECTS OF PRINCIPAL TEMPORARY DIFFERENCES THAT GIVE RISE TO DEFERRED TAX ASSETS	The tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of December 31, 2023 and 2022 are as follows: SCHEDULE OF TAX EFFECTS OF PRINCIPAL TEMPORARY DIFFERENCES THAT GIVE RISE TO DEFERRED TAX ASSETS 31-Dec-23 31-Dec-22 Years Ended 31-Dec-23 31-Dec-22 Deferred tax asset Net operating loss carryovers (federal) $ 13,561,765 $ 12,752,139 Total deferred tax assets 13,561,765 12,752,139 Valuation Allowance (13,561,765 ) (12,752,139 ) Deferred tax asset, net of allowance $ - $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF THE LEASE EXPENSE	The following table provides the components of the lease expense for the periods indicated: SCHEDULE OF COMPONENTS OF THE LEASE EXPENSE December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Finance Lease Cost: Amortization of ROU assets $ - $ - Interest on lease liabilities 0 0 Operating lease cost 95,172 86,601 Short-term lease cost 0 0 Total lease expense 95,172 86,601
SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES	The following table provides supplemental cash flow and other information related to leases for the periods indicated: SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases ( 1 $ - $ - Operating cash flows from finance leases 0 0 Financing cash flows from finance leases 0 0 ROU assets obtained in exchange for new lease liabilities: Finance leases 0 0 Operating leases 0 0 (1) Amounts are included in Other operating activities on the consolidated cash flow statements.
SCHEDULE OF LEASE TERMS AND DISCOUNT RATES	The following table provides the lease terms and discount rates for the periods indicated: SCHEDULE OF LEASE TERMS AND DISCOUNT RATES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Weighted-average remaining lease term (years): Finance leases 0 0 Operating leases 0.83 1.83 Weighted-average discount rate: Finance leases N/A N/A Operating leases N/A N/A
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES	The following table provides supplemental balance sheet information related to leases at the dates indicated: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES December 31, 2023 December 31, 2022 YEAR ENDED December 31, 2023 December 31, 2022 Assets Finance lease ROU assets (1) $ - $ - Operating lease ROU assets 81,091 178,399 Liabilities Current Finance lease liabilities 0 0 Operating lease liabilities 85,983 95,172 Noncurrent Finance lease liabilities 0 0 Operating lease liabilities 0 85,983 (1) Amounts are included in Property and equipment, net on the consolidated balance sheets.
SCHEDULE OF MATURITIES OF UNDISCOUNTED LEASE LIABILITIES	The following table provides maturities of undiscounted lease liabilities at December 31, 2023 SCHEDULE OF MATURITIES OF UNDISCOUNTED LEASE LIABILITIES Finance Lease Operating Lease 2024 $ - $ 88,365 2025 0 0 Thereafter 0 0 Total lease payments $ - $ 88,365 Less: Interest 0 (2,382 ) Present value of lease liabilities 0 85,983 Less: Current portion of lease obligation 0 (85,983 ) Total long-term lease obligation $ - $ 0 The following table provides maturities of undiscounted lease liabilities at December 31, 2022: Finance Lease Operating Lease 2023 $ - $ 103,465 2024 0 88,365 Thereafter 0 0 Total lease payments - 191,830 Less: Interest - (10,675 ) Present value of lease liabilities - 181,155 Less: Current portion of lease obligation - (95,172 ) Total long-term lease obligation - 85,983

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative)	1 Months Ended
	Jan. 31, 2024
Subsequent Event [Member] | Verti Blue Fuels LLC [Member]
Subsequent Event [Line Items]
Joint venture description	In January 2024, the Company formed a 50-50 joint venture partnership with Vertimass called VertiBlue Fuels, LLC, that has the mission to build an ethanol-to-SAF facility in Florida with the initial goal to produce around 10 million gallons of Sustainable Aviation Fuel (SAF) and related products, and then expand SAF and related product production to approximately 70 million gallon per year

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated losses	$ 55,836,780	$ 52,781,586

SCHEDULE OF BLACK-SCHOLES OPTIO

SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Issuance Date 01/05/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate		1.71%
Expected life		10 years
Expected dividends		0%
Expected volatility		133.99%
BIOF common stock fair value		$ 0.259
Issuance Date 04/19/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate		2.93%
Expected life		10 years
Expected dividends		0%
Expected volatility		133.42%
BIOF common stock fair value		$ 0.165
Issuance Date 06/21/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate		3.38%
Expected life		5 years
Expected dividends		0%
Expected volatility		134.52%
BIOF common stock fair value		$ 0.167
Issuance Date 09/30/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate		4.06%
Expected life		5 years
Expected dividends		0%
Expected volatility		128.59%
BIOF common stock fair value		$ 0.167
Issuance Date 12/30/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate		3.99%
Expected life		5 years
Expected dividends		0%
Expected volatility		124.11%
BIOF common stock fair value		$ 0.145
Issuance Date 02/10/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.93%
Expected life	5 years
Expected dividends	0%
Expected volatility	123.25%
BIOF common stock fair value	$ 0.159
Issuance Date 02/14/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.77%
Expected life	10 years
Expected dividends	0%
Expected volatility	123.26%
BIOF common stock fair value	$ 0.159
Issuance Date 03/01/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	4.01%
Expected life	10 years
Expected dividends	0%
Expected volatility	123.52%
BIOF common stock fair value	$ 0.177
Issuance Date 03/31/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.60%
Expected life	5 years
Expected dividends	0%
Expected volatility	120.71%
BIOF common stock fair value	$ 0.166
Issuance Date 04/05/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.30%
Expected life	10 years
Expected dividends	0%
Expected volatility	119.51%
BIOF common stock fair value	$ 0.154
Issuance Date 04/11/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.54%
Expected life	5 years
Expected dividends	0%
Expected volatility	119.39%
BIOF common stock fair value	$ 0.145
Issuance Date 04/26/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.46%
Expected life	5 years
Expected dividends	0%
Expected volatility	119.28%
BIOF common stock fair value	$ 0.165
Issuance Date 06/05/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.77%
Expected life	7 years
Expected dividends	0%
Expected volatility	103.20%
BIOF common stock fair value	$ 0.170
Issuance Date 07/13/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.93%
Expected life	5 years
Expected dividends	0%
Expected volatility	90.70%
BIOF common stock fair value	$ 0.160
Issuance Date 07/26/23 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.86%
Expected life	5 years
Expected dividends	0%
Expected volatility	87.22%
BIOF common stock fair value	$ 0.160
Issuance Date 10/16/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	4.72%
Expected life	5 years
Expected dividends	0%
Expected volatility	81.19%
BIOF common stock fair value	$ 0.131
Issuance Date 11/01/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	4.67%
Expected life	5 years
Expected dividends	0%
Expected volatility	81.11%
BIOF common stock fair value	$ 0.123
Issuance Date 12/27/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.78%
Expected life	5 years
Expected dividends	0%
Expected volatility	91.10%
BIOF common stock fair value	$ 0.106

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Research and development expenses	$ 1,849,967	$ 2,350,218
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	10 years

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 830,397	$ 547,293
Less Accumulated Depreciation	(243,089)	(127,178)
Property and Equipment	587,308	420,115
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 9,370	9,370
Estimated useful lives	15 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 795,606	512,450
Estimated useful lives	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 13,596	13,649
Estimated useful lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 11,825	$ 11,824
Estimated useful lives	3 years

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation	$ 119,476	$ 55,601
Purchase value	830,397	547,293
Laboratory Equipment And Machinery [Member]
Property, Plant and Equipment [Line Items]
Disposal of laboratory equipment and machinery	3,500	1,185
Purchase value	8,171	240,898
Accumulated depreciation	3,513	199,614
Loss on disposal of assets	$ 1,158	$ 40,099

PATENTS (Details Narrative)

PATENTS (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Patents, Gross	$ 254,786	$ 222,109

SCHEDULE OF NOTES PAYABLE (Deta

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Short Term Chapter 11 Settlement	$ 0	$ 50,000
Short Term Convertible Notes – Related Party	350,000	0
Long Term Convertible Notes Payable – Related Party	300,000	0
Long Term Notes Payable from future revenue — Related Party	1,700,630	1,700,630
Long Term Notes Payable from future revenue — Other	120,000	120,000
Long Term Note Payable from future profits — Related Party	820,932	820,932
Long Term Note Payable from future profits — Other	96,570	96,570
TOTAL NOTES	$ 3,388,132	$ 2,788,132

DEBT (Details Narrative)

DEBT (Details Narrative)

1 Months Ended

3 Months Ended

Dec. 13, 2023 USD ($) shares

Nov. 11, 2023 USD ($) $ / shares shares

Aug. 10, 2023 USD ($) shares

Jul. 07, 2023 USD ($) $ / shares shares

Jun. 30, 2023 USD ($) $ / shares shares

Jul. 18, 2018 USD ($) $ / shares

Jun. 30, 2018 USD ($)

May 15, 2018 USD ($) $ / shares shares

Feb. 28, 2018 USD ($) shares

Jun. 30, 2023 USD ($) $ / shares shares

Apr. 30, 2023 USD ($) $ / shares shares

Jan. 31, 2023 USD ($) $ / shares shares

May 31, 2018 USD ($)

Feb. 28, 2018 USD ($) shares

Nov. 30, 2017 USD ($) shares

Jul. 31, 2016 USD ($)

Mar. 31, 2023 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Mar. 27, 2019 USD ($)

Mar. 26, 2019 USD ($)

Feb. 28, 2017

Jun. 30, 2016

Debt Instrument [Line Items]

Total notes

$ 3,388,132

$ 2,788,132

Notes payable, noncurrent

$ 20,000

$ 32,000

Due out of long term at specific point

100,000

Debt instrument, converts into equity

300,000

Due out of long term on raising of capital

300,000

Due out of long term future revenue

2,738,132

Notes payable amount to be discharged

2,417,502

Notes Payable, Other Payables [Member] | AMG Energy Group [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 96,570

Debt interest rate

6%

Renegotiated notes, description

The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

Renegotiated amount

$ 96,570

Business acquisition, percentage

49%

Chris Kneppers [Member] | Convertible Debt One [Member]

Debt Instrument [Line Items]

Debt interest rate

10%

10%

10%

10%

Debt instrument, description

The Notes are convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 733,333 shares and warrants.

The Notes are convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 733,333 shares and warrants.

The Notes are convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 733,333 shares and warrants.

Debt instrument, term

5 years

5 years

5 years

Chris Kneppers [Member] | Convertible Debt Two [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 100,000

$ 100,000

Chris Kneppers [Member] | Convertible Debt Two [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

769,231

Convertible, conversion price per share | $ / shares

$ 0.13

$ 0.13

Chris Kneppers [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 250,000

Debt instrument, term

10 years

Chris Kneppers [Member] | Convertible Debt [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

1,923,077

Convertible, conversion price per share | $ / shares

$ 0.13

Chris Kneppers [Member] | Convertible Debt One [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 10,000

$ 50,000

$ 50,000

$ 50,000

Chris Kneppers [Member] | Convertible Debt One [Member] | Warrant [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

733,333

733,333

733,333

Edmund Burke [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 15,000

$ 25,000

$ 150,000

Debt instrument, term

5 years

Warrant, reason for issuance, description

accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 and 30,000 respectively every 12 months instead of interest, with a minimum of 80,000 warrants.

accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 and 30,000 respectively every 12 months instead of interest, with a minimum of 80,000 warrants.

accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.

Edmund Burke [Member] | Convertible Debt [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

307,692

307,692

1,153,846

Convertible, conversion price per share | $ / shares

$ 0.13

$ 0.13

$ 0.13

Related Party [Member]

Debt Instrument [Line Items]

Notes payable, noncurrent

$ 2,821,562

$ 2,521,562

Related Party [Member] | AMG Energy Group [Member]

Debt Instrument [Line Items]

Debt interest rate

6%

Renegotiated notes, description

The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019.

Mark Koch [Member] | AMG Energy Group [Member]

Debt Instrument [Line Items]

Renegotiated amount

$ 240,990

Animated Family Films [Member] | AMG Energy Group [Member]

Debt Instrument [Line Items]

Renegotiated amount

579,942

Minimum equity interest

1.25%

Steven Dunkle CTWC Wellington Asset Holdings [Member] | AMG Energy Group [Member]

Debt Instrument [Line Items]

Renegotiated amount

$ 1,500,000

Steven Sadaka [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 100,000

$ 100,000

Debt instrument maturity date

May 01, 2018

Amount to be paid out of future gross revenues

$ 100,000

Steven Sadaka [Member] | Loans Payable [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Stock issued during period, shares | shares

5,000,000

Steven Sadaka [Member] | Loans Payable [Member] | Inducement Shares [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

2,000,000

Conversion of convertible securities, value

$ 84,000

Christopher Jemapete [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 50,000

Debt interest rate

5%

Debt instrument maturity date

May 16, 2019

Amount to be paid out of future gross revenues

$ 50,315

Accrued interest, value

315

Christopher Jemapete [Member] | Loans Payable [Member] | Note Warrant [Member]

Debt Instrument [Line Items]

Debt instrument, term

5 years

Stock issued during period, shares | shares

1,000,000

Share price | $ / shares

$ 0.10

Stock issued during period, value

$ 24,449

Christopher Jemapete [Member] | Loans Payable [Member] | Inducement Shares [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

1,250,000

Conversion of convertible securities, value

$ 36,250

Pamela Jemapete [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 50,000

Debt interest rate

5%

Debt instrument maturity date

May 16, 2019

Amount to be paid out of future gross revenues

50,315

Accrued interest, value

$ 315

Pamela Jemapete [Member] | Loans Payable [Member] | Note Warrant [Member]

Debt Instrument [Line Items]

Debt instrument, term

5 years

Stock issued during period, shares | shares

1,000,000

Share price | $ / shares

$ 0.10

Stock issued during period, value

$ 24,449

Pamela Jemapete [Member] | Loans Payable [Member] | Inducement Shares [Member]

Debt Instrument [Line Items]

Shares, conversion of convertible securities | shares

1,250,000

Conversion of convertible securities, value

$ 36,250

Controller Dennis Lenaburg [Member] | Note Warrant [Member]

Debt Instrument [Line Items]

Stock issued during period, shares | shares

1,500,000

Controller Dennis Lenaburg [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Litigation amount payable

$ 2,694,577

Litigation on settlement

13,650

$ 50,000

Litigation amount payment

$ 50,000

Controller Dennis Lenaburg [Member] | Convertible Debt [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Convertible, conversion price per share | $ / shares

$ 0.30

Lucas Hoppel [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$ 165,000

$ 165,000

$ 143,000

Debt interest rate

8%

8%

8%

Shares, conversion of convertible securities | shares

500,000

500,000

Debt instrument maturity date

Sep. 21, 2018

May 30, 2018

Conversion of convertible securities, value

$ 14,500

$ 39,500

Original issue discount

$ 15,000

$ 15,000

$ 43,000

Debt instrument conversion discount rate, percentage

40

35

Prepayment penalty percentage

120%

120%

Debt instrument principal payments

$ 40,000

Total notes

$ 100,000

$ 100,000

$ 100,000

Percentage of future gross revenue

5%

5%

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option Shares Outstanding, Exercised	0	350,000
Option Shares Outstanding, Vested	4,385,000	12,560,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option Shares Outstanding, Beginning balance	51,080,000	50,034,466
Weighted Average Exercise Price, Beginning balance	$ 0.13	$ 0.13
Weighted Average Remaining Contractual Term (years), Beginning balance	7 years 10 months 13 days	8 years 6 months 10 days
Aggregate Intrinsic Value, Beginning balance	$ 6,791,500	$ 6,495,981
Option Shares Outstanding, Awarded	18,150,000	4,000,000
Weighted Average Exercise Price, Awarded	$ 0.19	$ 0.18
Weighted Average Remaining Contractual Term (years), Awarded	8 years 11 months 26 days	7 years 1 month 20 days
Aggregate Intrinsic Value, Awarded		$ 700,000
Option Shares Outstanding, Exercised	500,000	350,000
Weighted Average Exercise Price, Exercised	$ 0.05	$ 0.05
Aggregate Intrinsic Value, Exercised	$ 15,875	$ 15,900
Option Shares Outstanding, Expired	7,175,000	2,604,466
Weighted Average Exercise Price, Expired	$ 0.19	$ 0.15
Aggregate Intrinsic Value, Expired		$ 388,581
Option Shares Outstanding, Ending balance	61,555,000	51,080,000
Weighted Average Exercise Price, Ending balance	$ 0.15	$ 0.13
Weighted Average Remaining Contractual Term (years), Ending balance	7 years 2 months 12 days	7 years 10 months 13 days
Aggregate Intrinsic Value, Ending balance	$ 45,763	$ 6,791,500
Option Shares Outstanding, Vested	28,180,000	24,420,000
Weighted Average Exercise Price, Vested	$ 0.13	$ 0.12
Weighted Average Remaining Contractual Term (years), Vested	6 years 3 months 29 days	6 years 11 months 23 days
Aggregate Intrinsic Value, Vested	$ 42,500	$ 2,982,250

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding, Beginning balance	24,388,458	28,571,961
Weighted Average Exercise Price, Beginning balance	$ 0.16	$ 0.12
Weighted Average Remaining Contractual Term (years), Beginning balance	2 years 9 months 29 days	2 years 2 months 1 day
Aggregate Intrinsic Value, Beginning balance	$ 3,841,406	$ 3,352,149
Warrants Outstanding, awarded	7,478,998	7,863,997
Weighted Average Exercise Price, Issued	$ 0.24	$ 0.25
Weighted Average Remaining Contractual Term (years), Issued	4 years 4 months 6 days	4 years 9 months
Aggregate Intrinsic Value, Issued		$ 1,962,133
Warrants Outstanding, Exercised	5,450,148	7,000,000
Weighted Average Exercise Price, Exercised	$ 0.01	$ 0.02
Aggregate Intrinsic Value, Exercised	$ 373,299	$ 105,000
Warrants Outstanding, Expired	2,401,332	5,047,500
Weighted Average Exercise Price, Expired	$ 0.15	$ 0.27
Aggregate Intrinsic Value, Expired		$ 1,367,875
Warrants Outstanding, Ending balance	24,015,976	24,388,458
Weighted Average Exercise Price, Ending balance	$ 0.22	$ 0.16
Weighted Average Remaining Contractual Term (years), Ending balance	3 years 3 months 21 days	2 years 9 months 29 days
Aggregate Intrinsic Value, Ending balance	$ 91,690	$ 3,841,406
Warrants Outstanding, Vested	24,015,976	24,388,458
Weighted Average Exercise Price, Vested	$ 0.22	$ 0.16
Weighted Average Remaining Contractual Term (years), Vested	3 years 3 months 21 days	2 years 9 months 29 days
Aggregate Intrinsic Value, Vested	$ 91,690	$ 3,841,406

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Capital units, authorized	1,010,000,000
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	302,750,963	289,941,623
Common stock, shares outstanding	302,750,963	289,941,623
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Description of voting rights of common stock	Holders of shares of Common stock shall be entitled to cast one vote for each share held
Warrant issued for services	174,194	812,119
Number of shares issued for services, value	$ 29,300	$ 136,550
Warrants exercised share, shares	5,950,148	7,000,000
Warrants exercised	$ 97,251	$ 105,000
Stock options exercised, shares	0	350,000
Stock options vested	4,385,000	12,560,000
Unvested warrants issued		2,000,000
Stock options exercised		$ 15,900
Common stock rescinded, shares		11,043
Share-Based Payment Arrangement, Tranche One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock options vested	1,000,000
Number of stock options vested, value	$ 157,939
Employee and directors stock option plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
share based payment award options	17,150,000	2,000,000
Vesting period	10 years	10 years
Exercised price		$ 0.17
Value of share based payment award options	$ 2,835,613	$ 319,327
Stock options vested		12,560,000
Stock options, vested and expected to vest		100,000
Aggregate intrinsic value		$ 1,565,589
Employee and directors stock option plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock options vested	3,385,000
Number of stock options vested, value	$ 479,089
Employee and directors stock option plan [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercised price	$ 0.19
Employee and directors stock option plan [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercised price	$ 0.20
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares, new issues	6,684,998	7,786,664
Stock issued during period, value, new issues	$ 1,002,772	$ 1,168,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued for services	794,000	77,333
Number of shares issued for services, value	$ 84,677	$ 9,773

SCHEDULE OF RECONCILIATION BETW

SCHEDULE OF RECONCILIATION BETWEEN STATUTORY TAX RATE AND EFFECTIVE TAX RATE (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	(21.00%)	(21.00%)
State income tax, net of federal benefits	(5.50%)	(5.50%)
Valuation Allowance	26.50%	26.50%
Income tax provision (benefit)	0%	0%

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current
Deferred	(642,785)	(831,638)
Current
Deferred	(168,349)	(217,810)
Change in valuation allowance	811,134	1,049,448
Income tax provision (benefit)

SCHEDULE OF TAX EFFECTS OF PRIN

SCHEDULE OF TAX EFFECTS OF PRINCIPAL TEMPORARY DIFFERENCES THAT GIVE RISE TO DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax asset
Net operating loss carryovers (federal)	$ 13,561,765	$ 12,752,139
Total deferred tax assets	13,561,765	12,752,139
Valuation Allowance	(13,561,765)	(12,752,139)
Deferred tax asset, net of allowance

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Dec. 22, 2017	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Reconciliation of income tax benefit U.S.statutory rate		21%	21%
Operating loss carryovers, expiration date		2033
Operating loss carryovers, limitations on use		Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Reconciliation of income tax benefit U.S.statutory rate	35%
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Reconciliation of income tax benefit U.S.statutory rate		21%
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers		$ 51,176,471	$ 48,121,278

SCHEDULE OF COMPONENTS OF THE L

SCHEDULE OF COMPONENTS OF THE LEASE EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Amortization of ROU assets
Interest on lease liabilities	0	0
Operating lease cost	95,172	86,601
Short-term lease cost	0	0
Total lease expense	$ 95,172	$ 86,601

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases ()	[1]
Operating cash flows from finance leases		0	0
Financing cash flows from finance leases		0	0
Finance leases		0	0
Operating leases		$ 0	$ 0
[1]Amounts are included in Other operating activities on the consolidated cash flow statements.

SCHEDULE OF LEASE TERMS AND DIS

SCHEDULE OF LEASE TERMS AND DISCOUNT RATES (Details)	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Finance leases	0 years	0 years
Operating leases	9 months 29 days	1 year 9 months 29 days

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)		Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Finance lease ROU assets	[1]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property and equipment, net of accumulated depreciation and amortization of $243,089 and $127,178 at December 31, 2023 and December 31,2022, respectively	Property and equipment, net of accumulated depreciation and amortization of $243,089 and $127,178 at December 31, 2023 and December 31,2022, respectively
Operating lease ROU assets		$ 81,091	$ 178,399
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]		Right of Use Lease Liability - Current	Right of Use Lease Liability - Current
Finance lease liabilities		$ 0
Operating lease liabilities		$ 85,983	$ 95,172
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]		Right of Use Lease Liability - Current	Right of Use Lease Liability - Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]		Right of Use Lease Liability, net of current portion	Right of Use Lease Liability, net of current portion
Finance lease liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]		Right of Use Lease Liability, net of current portion	Right of Use Lease Liability, net of current portion
Operating lease liabilities			$ 85,983
[1]Amounts are included in Property and equipment, net on the consolidated balance sheets.

SCHEDULE OF MATURITIES OF UNDIS

SCHEDULE OF MATURITIES OF UNDISCOUNTED LEASE LIABILITIES (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Finance lease 2025
Operating lease 2024	88,365	103,465
Finance lease 2025	0	0
Operating lease 2025	0	88,365
Finance lease thereafter	0	0
Operating lease thereafter	0	0
Total Finance lease payments
Total operating lease payments	88,365	191,830
Finance lease Interest	0
Operating lease Interest	(2,382)	(10,675)
Finance lease present value of lease liabilities	0
Operating lease present value of lease liabilities	85,983	181,155
Finance lease current portion of lease obligation	0
Operating lease current portion of lease obligation	(85,983)	(95,172)
Finance lease long-term lease obligation
Operating lease long-term lease obligation		$ 85,983

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)				12 Months Ended
	Mar. 31, 2023 USD ($) a	Oct. 31, 2021 USD ($)	Sep. 01, 2020 USD ($) a	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Rent expense				$ 214,902	$ 139,083
Operating lease cost				$ 95,172	$ 86,601
Acres | a	167.6		18.2
Lease cost	$ 24,721		$ 6,370
Lease renewal term	5 years		5 years
Office and Laboratory Space [Member]
Property, Plant and Equipment [Line Items]
Lease extension period				This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024.
Rent expense		$ 84,100		$ 102,950
Percentage of increase in rent per year				3%
Operating lease cost				$ 3,600

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		12 Months Ended
	Jan. 01, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Issuance of common stock for services		174,194	812,119
Issuance of common stock for services, value		$ 29,300	$ 136,550
Vesting of options previously issued under employee director plan		4,385,000	12,560,000
Issuance of common stock in exchange for debt
Equity Option [Member]
Subsequent Event [Line Items]
Vesting of options previously issued under employee director plan		28,180,000	24,420,000
Stock options vested		$ 42,500	$ 2,982,250
Subsequent Event [Member] | Related Party [Member]
Subsequent Event [Line Items]
Issuance of common stock in exchange for debt	$ 230,000
Subsequent Event [Member] | Equity Option [Member]
Subsequent Event [Line Items]
Vesting of options previously issued under employee director plan	1,775,000
Stock options vested	$ 234,350
Common Stock [Member]
Subsequent Event [Line Items]
Issuance of common stock for services		174,194	812,119
Issuance of common stock for services, value		$ 174	$ 812
Common Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of common stock for services	52,500
Issuance of common stock for services, value	$ 4,200
Warrant [Member]
Subsequent Event [Line Items]
Issuance of common stock for services		794,000	77,333
Issuance of common stock for services, value		$ 84,677	$ 9,773
Warrant [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of common stock for services	62,500
Issuance of common stock for services, value	$ 3,592
Number of warrants expired	133,333